Tsai Fuu-Jen, Li Te-Mao, Ko Cheng-Hang, Cheng Chi-Fung, Ho Tsung-Jung, Liu Xiang, Tsang Hsinyi, Lin Ting-Hsu, Liao Chiu-Chu, Li Ju-Pi, Huang Shao-Mei, Lin Jung-Chun, Lin Chih-Chien, Liang Wen-Miin, Lin Ying-Ju
School of Chinese Medicine, China Medical University, Taichung, Taiwan.
Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Oncotarget. 2017 Jun 29;8(38):63528-63550. doi: 10.18632/oncotarget.18846. eCollection 2017 Sep 8.
Diabetic retinopathy is a microvascular complication of type 2 diabetes and the leading cause of acquired blindness. In Taiwan, Chinese herbal medicine (CHM) is a popular adjunctive therapy. In this study, we investigated the CHM prescription patterns and their effects. We identified 23,701 subjects with type 2 diabetes in a database, and after matching for age and gender, 6,948 patients each were assigned to CHM and non-CHM groups. In the female subgroups, the cumulative retinopathy probability was lower for the CHM users than that for the CHM non-users ( < 0.001, log-rank test). Among the top 10 CHMs, Jia-Wei-Xiao-Yao-San (JWXYS; 52.9%), Shu-Jing-Huo-Xue-Tang (SJHXT; 45.1%), and Ge-Gen-Tang (GGT; 43.7%) were the most common herbal formulas. Yan-Hu-Suo (48.1%), Ge-Gen (42.1%), and Huang-Qin (HQin; 40.1%) were the most common single herbs. CHM network analysis showed that JWXYS was the core CHM of cluster 1. JWXYS, DS, XF, and SZRT exhibited both of the reductions of HO-induced phosphorylation of p38 MAPK and p44/42 MAPK (Erk1/2) in human ARPE-19 retina cells. In cluster 2, SJHXT was the core CHM. SJHXT and NX showed both of the phosphorylation reductions. In cluster 3, GGT was the core CHM, and it reduced the phosphorylation of both MAPKs. In cluster 4, HQin was the core CHM, and it also reduced the phosphorylation of both MAPKs. Our study suggests that adjunctive CHM therapy may reduce diabetic retinopathy via antioxidant activity of the herbs and provides information on core CHM treatments for further scientific investigations or therapeutic interventions.
糖尿病视网膜病变是2型糖尿病的一种微血管并发症,也是后天性失明的主要原因。在台湾,中药是一种常用的辅助治疗方法。在本研究中,我们调查了中药的处方模式及其效果。我们在一个数据库中识别出23701名2型糖尿病患者,在匹配年龄和性别后,将6948名患者分别分配到中药组和非中药组。在女性亚组中,使用中药的患者视网膜病变累积概率低于未使用中药的患者(对数秩检验,P<0.001)。在最常用的10种中药中,加味逍遥散(52.9%)、舒筋活血汤(45.1%)和葛根汤(43.7%)是最常见的中药方剂。延胡索(48.1%)、葛根(42.1%)和黄芩(40.1%)是最常见的单味中药。中药网络分析表明,加味逍遥散是第1组的核心中药。加味逍遥散、丹参、小檗碱和四物汤在人ARPE-19视网膜细胞中均表现出降低HO诱导的p38丝裂原活化蛋白激酶和p44/42丝裂原活化蛋白激酶(Erk1/2)磷酸化的作用。在第2组中,舒筋活血汤是核心中药。舒筋活血汤和牛膝均表现出磷酸化降低的作用。在第3组中,葛根汤是核心中药,它降低了两种丝裂原活化蛋白激酶的磷酸化。在第4组中,黄芩是核心中药,它也降低了两种丝裂原活化蛋白激酶的磷酸化。我们的研究表明,辅助中药治疗可能通过草药的抗氧化活性降低糖尿病视网膜病变,并为进一步的科学研究或治疗干预提供核心中药治疗的信息。